[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kirby Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":288},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,50,73,104,138,162,187,215,239,259],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100632086","phase-2-semaglutide-for-treatment-of-people-with-methamphetamine-use-disorder-the-shift-study-100632086",false,"NCT07509112","Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study","SHIFT","Inclusion Criteria:\n\n1. Has provided voluntary, written informed consent;\n2. Aged 18 years or older;\n3. Diagnosed with moderate to severe methamphetamine use disorder (DSM-5 criteria);\n4. Self-reported methamphetamine use on at least 14 of past 28 days and a positive oral fluid drug screen for amphetamine\u002Fmethamphetamine;\n5. Willing and able to comply with study procedures and follow-up visits;\n6. People of child-bearing potential must agree to use effective contraception during treatment and during the 60 days after treatment end.\n\nExclusion Criteria:\n\n1. Uncontrolled medical or psychiatric conditions that may interfere with participation;\n2. Body mass index less than 22 kg\u002Fm2;\n3. Confirmed diagnosis of diabetes mellitus (either known history of diabetes; concomitant treatment with insulin, metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitor, DPP4 inhibitor; or HbA1c \\>6.5 at screening);\n4. Currently taking a GLP-1 receptor agonist;\n5. Known hypersensitivity or contraindications to GLP-1 receptor agonists as per product information;\n6. Current enrolment in another interventional trial;\n7. Lactating, pregnant or at risk of pregnancy not willing to avoid pregnancy\n8. History of pancreatitis;\n9. History of medullary thyroid cancer;\n10. Current admission to a residential rehabilitation program or inpatient program or planned admission during the study period, which would interfere with participation in study visits or procedures;\n11. Currently experiencing psychosis or current active suicidality\n12. Any condition or circumstance that, in the opinion of the investigator, would compromise the participant's ability to comply with the study procedures, complete protocol requirements, or provide reliable data.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.",[26],"Methamphetamine Use Disorder",[28,29,30,31,32,33,34,35,36],"Substance use disorder","Addiction","Drug use","Methamphetamine","Stimulants","GLP-1","Semaglutide","Ozempic","Wegovy","NOT_YET_RECRUITING","2026-06-23",{"date":40,"type":41},"2026-06-26","ACTUAL",{"date":43,"type":20},"2026-09",{"date":45,"type":20},"2027-03",{"name":47,"class":48},"Kirby Institute","OTHER_GOV",5,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100432707","real-world-assessment-of-people-living-with-chronic-hepatitis-b-in-australia-100432707","NCT04914611","Real World Assessment of People Living With Chronic Hepatitis B in Australia","REACH-B","Inclusion Criteria:\n\n1. All individuals diagnosed with chronic hepatitis B in the participating study sites are eligible to be included (both newly diagnosed cases and those diagnosed in the past).\n2. 16 years of age or older.\n3. Attended the health service for HBV care within the prior 12 months from study commencement (retrospective recruitment) OR Attending the health service for HBV care from study commencement (prospective recruitment)\n\nExclusion Criteria:\n\n1\\. Nil",{"count":58,"type":20},10000,"OBSERVATIONAL","The REACH-B study establishes an observational cohort study of people living with chronic hepatitis B from a national network, including a diverse range of services, to characterise and monitor hepatitis B linkage to care and treatment requirements amongst this population.",[62],"Hepatitis B","RECRUITING","2026-05-18",{"date":66,"type":41},"2026-05-19",{"date":68,"type":41},"2022-02-17",{"date":70,"type":20},"2030-07-31",{"name":47,"class":48},19,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100338330","ethos-engage-enhancing-treatment-of-hepatitis-c-in-opioid-substitution-settings-100338330","NCT03685045","ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings","Enhancing Treatment of Hepatitis C in Opioid Substitution Settings II (ETHOS II): A Partnership Project to Enhance Hepatitis C Care in Drug and Alcohol Clinics","ETHOS II","Inclusion Criteria:\n\n* Participant has voluntarily signed the informed consent form;\n* 18 years of age or older;\n* History of injecting drug use\\*;\n* Recent injecting drug use (previous six months) or currently receiving OST\\*.\n\n  * These criteria will not apply for recruitment from residential rehabilitation centres\n\nExclusion Criteria:\n\n* Nil",true,{"count":83,"type":20},6000,[85],"NA","The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.",[88],"Hepatitis C",[90,91,92,93,94],"hepatitis c","opioid substitution settings","OST","people who inject drugs","direct-acting antiviral treatment","2026-05-11",{"date":97,"type":41},"2026-05-14",{"date":99,"type":41},"2018-05-28",{"date":101,"type":20},"2028-12-31",{"name":47,"class":48},32,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100635277","phase-2-oritavancin-for-treatment-of-serious-cardiac-infections-100635277","NCT07550595","Oritavancin for Treatment of Serious Cardiac Infections","A Multicentre Phase II Prospective Pilot Study of Pharmacokinetic- and TDM-guided Oritavancin Dosing Strategies for the Management of Gram-positive Cardiac Infections (the OSCAR Study)","OSCAR","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalised for management of a cardiac infection (infective endocarditis or cardiovascular implantable electronic device infections)\n3. Gram-positive organism identified in blood or tissue culture, that in the opinion of the investigator is the cause of cardiac infection and would be treatable with a finite antibiotic duration (e.g., 4-6 weeks)\n4. Afebrile for at least 24 hours at screening\n5. Clearance of blood cultures for at least 24 hours at screening\n6. Receiving effective antibiotic therapy for at least 24 hours and no more than 14 days at screening\n7. Willingness of both treating provider and participant to proceed with oritavancin therapy\n8. Able to provide written informed consent\n9. Willingness and ability to participate in study procedures, including follow-up visits and drug monitoring\n\nExclusion Criteria:\n\n1. History of severe allergic reaction or hypersensitivity to oritavancin or any of its components\n2. Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or currently receiving dialysis\n3. Severe hepatic impairment (Child-Pugh class C)\n4. Current infection involving the central nervous system, including septic emboli, ischemic or haemorrhagic stroke, epidural abscess, or meningitis (excluding prior\u002Funrelated central nervous system events).\n5. Presence of prosthetic heart valve\n6. Culture negative endocarditis\n7. Presence of any other active infection requiring concurrent antibiotic treatment that could interfere with study outcomes\n8. Infection with Gram positive organism not susceptible to oritavancin or vancomycin (vancomycin MIC \\> 2 μg\u002FmL).\n9. Use of contraindicated medications (see Section 8)\n10. Participation in another interventional clinical trial that may confound study outcomes\n11. Pregnant or breastfeeding people, or those planning to become pregnant during the study period (people of childbearing potential must have a negative pregnancy test during hospitalization and use effective contraception for trial duration and for 3 months after last infusion of study medication).\n12. Immunosuppression (defined as active chemotherapy expected to cause absolute neutrophil count \\\u003C100 cells\u002Fmm3 lasting \\>7 days during the study period, bone marrow transplantation in the preceding 90 days, solid organ transplantation within prior 3 months or receipt of augmented immunosuppression for rejection within 3 months, chronic granulomatous disease, HIV with a CD4 count \\\u003C50 cells\u002Fmm3 based on last known measure).\n13. Any condition (e.g. severe cognitive impairment, psychiatric illness, active withdrawal) that, in the opinion of the investigator, would limit the participant's ability to comply with study procedures or give informed consent\n14. Medically unstable in opinion of treating clinician that would preclude participation\n15. Cases in which the investigator deem curative or finite antibiotic treatment unlikely (e.g., long term indefinite suppressive antibiotics are likely such as retained hardware).",{"count":113,"type":20},20,[23],"Cardiac infections, including infective endocarditis and cardiovascular implantable electronic device infections, are associated with substantial morbidity and mortality and are commonly caused by gram-positive bacteria. Standard management typically requires prolonged courses of intravenous antibiotics and extended hospitalisation, which are costly, burdensome, and associated with complications related to long-term vascular access. People who inject drugs are disproportionately affected and often experience stigma, barriers to care, and poorer outcomes. Long-acting lipoglycopeptides such as oritavancin maintain therapeutic serum concentrations for prolonged periods and may offer an alternative to conventional intravenous antibiotic regimens. Oritavancin is not TGA-registered in Australia and is accessed as an unregistered medicine (for example, via SAS or clinical trials). It is approved in other jurisdictions, including the United States and European Union, for acute bacterial skin and skin structure infections. Prospective data in cardiac infections remain limited, and optimal dosing strategies, including the role of therapeutic drug monitoring, are uncertain. This multicentre, open-label pilot study will assess the feasibility, pharmacokinetics, safety, acceptability, and preliminary efficacy of oritavancin for gram-positive cardiac infections using both standard fixed dosing and TDM-guided dosing strategies. Findings will inform PK\u002FPD modelling, the potential role of TDM, and the design of future larger-scale trials and models of care, including alternatives to prolonged inpatient intravenous therapy.",[117,118,119],"Infective Endocarditis","Cardiac Device Infection","Gram-positive Bacterial Infections",[121,122,123,124,125,126,127,128],"Oritavancin","Long-acting antibiotic","Lipoglycopeptide","Infective endocarditis","Cardiac device infection","Gram-positive infection","Therapeutic drug monitoring","Pharmacokinetics","2026-04-23",{"date":131,"type":41},"2026-04-29",{"date":133,"type":20},"2026-07-01",{"date":135,"type":20},"2028-09-30",{"name":47,"class":48},3,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":146,"targetDuration":148,"studyType":59,"phases":4,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},"100442527","the-australian-hcv-point-of-care-testing-program-100442527","NCT05042544","The Australian HCV Point-of-Care Testing Program","The National Australian HCV Point-of-Care Testing Program: An Observational Cohort Study to Evaluate the Use of Finger-stick Point-of-care Hepatitis C Testing to Enhance Diagnosis and Treatment of HCV Infection","HCVPOCT","Inclusion Criteria:\n\n1. Provided informed consent.\n2. ≥ 18 years of age.\n3. Have a risk factor for the acquisition of HCV infection (including current or past injecting drug use, previous incarceration, HIV infection, receiving blood products prior to 1990, having a tattoo or piercing in an unregulated environment, a needle-stick injury, or a mother with HCV).\n\n   OR:\n4. Are attending a service caring for people with risk factors for the acquisition of HCV infection (e.g. drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, and homelessness services).\n\nExclusion Criteria:\n\na. Is unable or unwilling to provide informed consent or abide by the requirements of the study.",{"count":147,"type":20},60000,"12 Months","The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). Participants will attend a single visit to have their HCV RNA status tested and complete a self-administered survey. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.",[88],[152],"Hepatitis C Virus","2026-03-26",{"date":155,"type":41},"2026-03-31",{"date":157,"type":41},"2022-02-22",{"date":159,"type":20},"2029-06-30",{"name":47,"class":48},69,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":49},"100471161","phase-3-immunosuppression-and-covid-19-boosters-100471161","NCT05415267","Immunosuppression and COVID-19 Boosters","Comparison of Immunity-boosting Regimens for COVID-19 Upon Initiation of Immunosuppressive Therapy","Inclusion Criteria:\n\n* Adult aged at least 18 years\n* Previously vaccinated with 2 (or more) doses of any licensed COVID-19 vaccine who requires initiation of moderate-to-severe immunosuppression; most recent COVID-19 vaccine dose must have been given \\> 3 months prior\n* Planned significant immunosuppressive therapy for at least 1 year\n* No cyclophosphamide, alemtuzumab or rituximab treatment in the past 5 years. Note: patient may have concurrent steroids with any treatments listed in protocol\n* Voluntarily given written informed consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Has underlying primary immunodeficiency\n* Has received or likely to receive intravenous\u002Fsubcutaneous immunoglobulin (IVIg\u002FScIg).\n* Projected treatment is likely to involve plasma exchange\n* Contraindication to receipt of SARS-CoV-2 vaccine\n* Intolerance of or previous allergic reaction to tetanus vaccination\n* Patients switching immunosuppressive therapies following enrolment with an absolute lymphocyte count \\<0.5 x 109\u002FL immediately prior to screening",{"count":170,"type":20},320,[172],"PHASE3","It is important people receiving immunosuppressive therapy are provided with the best protection against COVID-19 because they are at greater risk of severe illness should they become infected. As severe immunosuppression can reduce the efficacy of COVID-19 vaccination, doctors agree that COVID-19 boosters is are important to maximise the vaccine response in these people. However, we don't currently know the best time to give booster vaccines to people about to start immunosuppressive therapy. This research aims to address this knowledge gap by examining whether the greatest protection is provided by giving the COVID-19 booster just before the immunosuppressive therapy starts or by waiting and giving the booster 6 months after treatment start. At the 6-month timepoint, in many cases the more intensive immunosuppression is often weaning and the immune system is starting to rebuild.",[175],"COVID-19",[177,178],"Vaccination","Immunology","2026-02-21",{"date":181,"type":41},"2026-02-24",{"date":183,"type":41},"2023-07-21",{"date":185,"type":20},"2026-12-31",{"name":47,"class":48},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":81,"sex":16,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":21,"phases":198,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":213,"locationsCount":214},"100604147","phase-4-moxidectin-versus-ivermectin-as-mass-drug-administration-for-the-control-of-onchocerciasis-and-other-neglected-tropical-diseases-100604147","NCT07145736","Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases","Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial","EKAIO","Inclusion Criteria:\n\n* Male or female children and adults\n* Residents in the villages selected for MDA treatment\n\nExclusion Criteria:\n\n* Arm 1 (ivermectin): children under the age of 5 and\u002For under 90 cm of height\n* Arm 2 (moxidectin): children under the age of 12 years (who will receive ivermectin if they are at least 90 cm in height\u002F5 years of age and above).\n* Arm 1 (ivermectin): Women breast-feeding babies under 45 days of age\n* Arm 2 (moxidectin): All breastfeeding women (who will be offered ivermectin if their infants is at least 45 days old)\n* Know allergy to ivermectin or moxidectin\n* Attending other clinical trials during the study\n* Pregnant\n* Arm 2 (moxidectin): Women planning to become pregnant in the 3 months post-treatment\n* Refusal to receive one or both study drugs, i.e. participants in villages allocated to receive moxidectin who refuse to receive moxidectin will be given the option to receive ivermectin; if they refuse to receive both drugs they will be excluded from the MDA altogether\n* Has an illness that makes them too sick or weak to get out of bed\n* Currently hospitalized","5 Years",{"count":197,"type":20},52000,[199],"PHASE4","This clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States Food and Drug Administration (FDA) to treat this disease. The study also explores how these treatments affect other infections common in the region, including intestinal worms (soil-transmitted helminths) and scabies.\n\nThe trial aims to answer the following key questions:\n\n* How do moxidectin and ivermectin compare in reducing the prevalence (how common the disease is) and intensity (amount of parasites per person) of onchocerciasis in the community?\n* Do the treatments differ in their effect on the prevalence and intensity of soil-transmitted helminths and the prevalence of scabies?\n* Does moxidectin reduce transmission of onchocerciasis more effectively than ivermectin, based on genetic testing of parasites in people and lab testing of the blackflies that carry the infection?\n* How many more years of treatment would be needed to reach elimination with each drug, based on mathematical disease modelling?\n* How do communities feel about receiving moxidectin versus ivermectin, and what factors help or make it harder to carry out MDA programs with moxidectin versus ivermectin?\n\nThe study takes place in Bié Province, Angola, and involves 20 groups of villages randomly assigned to receive either moxidectin or ivermectin once a year for four years. Prior to every round of MDA, researchers will collect skin, stool and blood samples from a sample of the people living in the study area. We believe the results will help guide global policy on the use of moxidectin in efforts to eliminate onchocerciasis and control related diseases.",[202,203,204,205,206],"Onchocerciasis","Ascaris Lumbricoides Infection","Trichuris Trichiura; Infection","Hookworm Infections","Scabies","2025-11-18",{"date":209,"type":41},"2025-11-21",{"date":211,"type":41},"2025-08-04",{"date":159,"type":20},{"name":47,"class":48},1,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},"100494050","the-national-australian-hcv-point-of-care-testing-program---hcv-antibody-testing-minimal-dataset-100494050","NCT05713136","The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset","The National Australian HCV Point-of-Care Testing Program: An Observational Cohort Study to Evaluate the Use of Finger-stick Point-of-care Hepatitis C Testing to Enhance Diagnosis and Treatment of HCV Infection - HCV Antibody Testing Minimal Dataset","Inclusion Criteria:\n\n* Provide informed consent\n* ≥ 18 years of age.\n\nExclusion Criteria:\n\n* Is unable or unwilling to provide informed consent",{"count":223,"type":20},40000,"The goal of this observational study is to learn if offering a point-of-care screening test for exposure to the Hepatitis C virus, before providing a diagnostic test for Hepatitis C infection can increase testing, diagnosis and treatment in Adults. Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of Hepatitis C viral infection. The main question it aims to answer is:\n\nWhat proportion of the participants that have been diagnosed with HCV infection have started treatment when their records are reviewed 12 weeks after diagnosis?\n\nParticipants will have one in-person visit where they will provide informed consent and receive a finger-prick rapid result test for Hepatitis C infection. Participants with no previous Hepatitis C infection will have a screening test to see if they have an immune reaction to Hepatitis C. Participants who know they have been infected with Hepatitis C in the past, and all participants with a positive screening test result will then be given a Hepatitis C diagnostic test at this visit.\n\nNo treatment is provided as a part of this study, participants who are diagnosed with Hepatitis C infection will be referred to testing locations standard of care for any additional clinical assessments and treatment initiation. A review of the participant's records will be made 12 weeks after their Hepatitis C result and their treatment data are gathered.",[88],[227,228,229],"Point-of-Care","Rapid Diagnostic Testing","HCV","2024-07-02",{"date":232,"type":41},"2024-07-03",{"date":234,"type":41},"2023-01-25",{"date":236,"type":20},"2027-01",{"name":47,"class":48},12,{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},"100458356","the-national-australian-hcv-point-of-care-testing-program---minimal-dataset-100458356","NCT05248555","The National Australian HCV Point-of-Care Testing Program - Minimal Dataset","The National Australian HCV Point-of-Care Testing Program: An Observational Cohort Study to Evaluate the Use of Finger-stick Point-of-care Hepatitis C Testing to Enhance Diagnosis and Treatment of HCV Infection - Minimal Dataset","Inclusion Criteria:\n\n* ≥ 18 years of age.\n* Received point-of-care HCV testing.\n\nExclusion Criteria:\n\n* Nil",{"count":223,"type":20},"The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.",[88],[152],"2024-06-11",{"date":252,"type":41},"2024-06-13",{"date":254,"type":41},"2021-12-01",{"date":256,"type":20},"2026-12",{"name":47,"class":48},11,{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":268,"conditions":269,"keywords":276,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":4},"100533019","path-study-people-with-injecting-related-infections-assessing-treatment-outcomes-for-those-who-are-hospitalised-100533019","NCT06220370","PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised.","PATH","Inclusion Criteria:\n\n1. Have voluntarily signed the informed consent form,\n2. 18 years of age or older,\n3. Injected drugs within the last 6 months,\n4. Admitted to hospital with invasive bacterial or fungal infection, a. Examples of invasive infection include: bloodstream infection, bone and joint infection (osteomyelitis, septic arthritis, discitis), central nervous system infection (epidural abscess, meningitis), deep abscess (i.e., brain, liver, muscle, spleen), endovascular infection (infective endocarditis, septic thrombophlebitis, mycotic aneurysm, septic embolism), skin or soft tissue infection (necrotising fasciitis, myositis),\n\nExclusion Criteria:\n\n1\\) Is unable or unwilling to provide informed consent or abide by the requirements of the study.",{"count":267,"type":20},300,"We seek to characterise the burden and outcomes of and understand the current experience of people who inject drugs admitted to hospital with invasive injecting-related infections, in order to implement and evaluate strategies to improve completion of therapy and reduce patient-directed discharges, with ultimate benefit to the patient and health service.",[270,271,272,273,274,275],"Invasive Fungal Infections","Invasive Bacterial Infection","Injection Site Infection","Infection, Bacterial","Infection, Fungal","Infection, Soft Tissue",[277,278,279],"Antimicrobial therapy","Patient-directed discharge","Injection-related infectious diseases","2024-02-18",{"date":282,"type":41},"2024-02-20",{"date":284,"type":20},"2024-03-01",{"date":286,"type":20},"2029-03-01",{"name":47,"class":48},""]